Table 2.
Multivariable analysis for survival outcomes
| Variable | LRC (HR, P value) | DFS (HR, P value) | DMFS (HR, P value) | OS (HR, P value) |
|---|---|---|---|---|
| CRT (+/−) | 1.54, P = .57 | 0.78, P = .37 | 0.88, P = .80 | 1.59, P = .42 |
| Stage (3/4 vs 1/2) | 2.67, P < .01 | 3.91, P < .01 | 2.80, P = .04 | 4.67, P = .02 |
|
# of RF: 2–3 vs 0‐1; 4‐6 vs 0‐1; 4‐6 vs 2‐3 |
‐ | 3.04, P = .03 | 3.38, P = .03 | 3.84, P = .04 |
| 3.98, P = .02 | 5.78, P < .01 | 5.42, P = .02 | ||
| 1.31, P = .49 | 1.71, P = .19 | 1.41, P = .45 | ||
| Overall F test of entire model | P < .01 | P < .01 | P < .01 | P < .01 |
Note: Bold P values indicate statistical significance or trend.
Abbreviations: CRT, chemoradiation; DFS, disease‐free survival; DMFS, distant metastasis‐free survival; HR, hazard ratio; LRC, locoregional control; OS, overall survival; RF, risk factors (lymph node positivity, extranodal extension, lymphovascular space invasion, perineural invasion, positive/close surgical margin, grade 3).